Abstract:Abstract Background Lower influenza vaccine effectiveness (VE) against circulating H3N2 strains compared with other influenza viruses is partly explained by antigenic mismatch between circulating strains and the vaccine strain (Belongia 2016). This mismatch has recently been linked to a new glycosylation site introduced in the egg-adaptation step (Zost 2017) and HA L194P substitution (Wu 2017) for H3N2. Vaccine manufactured using seed virus wholly grown in mammalian (e.g., Madin–Darby Canine Kidney—MDCK) cells, as with the NH17-18 version of Flucelvax®, avoids these mutations. Preliminary reports suggest that this cell-based vaccine showed greater VE than did similar egg-based vaccines [FDA Statement]. This study aimed to compile existing data on antigenic similarity to measure the degree of match with circulating wild-type isolates of egg- and MDCK-propagated versions of the vaccine H3N2 virus over multiple seasons. Methods Using publicly available reports from the Worldwide Influenza Centre, London (Crick), we compiled data on antigenic similarity, defined as H3N2 circulating wild-type virus isolates showing no more than a 4-fold reduction in titer to antisera raised against wholly MDCK- or egg-propagated versions of the vaccine H3N2 viruses. Titers were compared using hemagglutination inhibition (HI) assays and/or plaque reduction neutralization assays (PRNA). Results Data from Northern Hemisphere influenza seasons of 2011–2012 to 2017–2018 show a substantially higher proportion of tested circulating influenza H3N2 viruses matched the MDCK-propagated reference viruses than did corresponding egg-propagated reference vaccine viruses (Figures 1 and 2). In half of the seasons evaluated, there was little to no antigenic similarity between circulating viruses and the egg-based vaccine viral seed. Conclusion These data suggest higher levels of mismatch have occurred consistently with egg-propagated H3N2 reference viruses compared with MDCK-propagated reference viruses when measured against circulating wild-type isolates and may further explain the potential for lower VE observed against H3N2 historically. Furthermore, these data point to the importance of continuing to utilize cell-derived seeds in creating seasonal influenza vaccines for this strain. Disclosures S. Rajaram, Seqirus: Employee, Salary. J. Van Boxmeer, Seqirus: Employee, Salary. B. Leav, Seqirus: Employee and Shareholder, Salary. P. Suphaphiphat, Seqirus: Employee, Salary. I. Iheanacho, Seqirus: Consultant, Research support. K. Kistler, Seqirus: Consultant, Research support.

Influenza Virus Vaccine Efficacy Based On Conserved Sequence Alignment

Applying Unique Molecular Identifiers in Next Generation Sequencing Reveals a Constrained Viral Quasispecies Evolution under Cross-Reactive Antibody Pressure Targeting Long Alpha Helix of Hemagglutinin

Recent Advances, Approaches and Challenges in the Development of Universal Influenza Vaccines

Influenza Vaccine Effectiveness and Progress Towards a Universal Influenza Vaccine

2556. Retrospective Evaluation of Mismatch From Egg-Based Isolation of Influenza Strains Compared With Cell-Based Isolation and the Possible Implications for Vaccine Effectiveness

Current challenges: from the path of "original antigenic sin" towards the development of universal flu vaccines

Progress towards the Development of a Universal Influenza Vaccine

How far have we reached in development of effective influenza vaccine?

A general solution to broad-spectrum vaccine design for rapidly mutating viruses

Influenza Vaccine: An Engineering Vision from Virological Importance to Production

Vaccine approaches conferring cross-protection against influenza viruses

Towards a universal influenza vaccine: different approaches for one goal

Prediction of Influenza B Vaccine Effectiveness from Sequence Data

Targeting Hemagglutinin: Approaches for Broad Protection against the Influenza A Virus

A call to cellular & humoral arms: Enlisting cognate T cell help to develop broad-spectrum vaccines against influenza A

Recent Progress in Recombinant Influenza Vaccine Development Toward Heterosubtypic Immune Response

Influenza vaccine: progress in a vaccine that elicits a broad immune response

Flu Universal Vaccines: New Tricks on an Old Virus

Influenza Immunization Elicits Antibodies Specific for an Egg-Adapted Vaccine Strain.

Computer-assisted vaccine design

Influenza B Virus Vaccine Innovation through Computational Design